A new molecule would slow cognitive decline in the early stages of the disease
Should we rejoice in the new treatment validated by the American Medicines Agency (FDA)? It is still too early to claim victory. And yet, this new molecule against Alzheimer’s, aimed at reducing the cognitive decline of patients suffering from this neurodegenerative disease, is eagerly awaited after the failed launch of a previous drug with a similar mechanism a year and a half ago. The new treatment, which will be marketed by the pharmaceutical company Eisai under the name Leqembi, is now recommended for patients who have not yet reached an advanced stage of the disease. It represents ‘an important step forward in our battle to tr
Related posts:
"Preventing Exercise Headaches: Tips and Techniques to Stay Pain-Free During and After Physical Acti...
A history of fighting for patients
India Beats Defending Champions Japan in Asian Games Hockey: A Victory for Team India
Stan Wawrinka and Dominic Stricker Excel in Swiss Open Doubles, Heading to Finals in Gstaad
Red Bull F1 leader, Ferrari / Leclerc's mistake "thank you"[F1-Gate .com]
The significant impact of medical cannabis on one of the body's systems
Ways stress can affect your oral hygiene
The story of the woman from Cali whose truck was stolen with her dogs inside; one could die for lac...